Free Trial
NASDAQ:GMTX

Gemini Therapeutics (GMTX) Stock Price, News & Analysis

Gemini Therapeutics logo
$61.59 +0.19 (+0.31%)
As of 09/3/2025

About Gemini Therapeutics Stock (NASDAQ:GMTX)

Key Stats

Today's Range
$60.19
$63.51
50-Day Range
$51.13
$61.59
52-Week Range
$1.16
$14.10
Volume
325,465 shs
Average Volume
189,291 shs
Market Capitalization
$2.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive GMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GMTX Stock News Headlines

Washington prepares for war
While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.tc pixel
See More Headlines

GMTX Stock Analysis - Frequently Asked Questions

Gemini Therapeutics' stock was trading at $63.40 at the beginning of the year. Since then, GMTX shares have decreased by 2.9% and is now trading at $61.59.

Gemini Therapeutics, Inc. (NASDAQ:GMTX) announced its earnings results on Monday, November, 15th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.04.

Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gemini Therapeutics investors own include Alphabet (GOOG), Meta Platforms (META), NVIDIA (NVDA), Zoom Communications (ZM), Activision Blizzard (ATVI), Fiverr International (FVRR) and Shopify (SHOP).

Company Calendar

Last Earnings
11/15/2021
Today
9/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GMTX
CIK
1816736
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$71.87 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-38.78%
Return on Assets
-35.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
71.49
Quick Ratio
71.49

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.89 per share
Price / Book
21.31

Miscellaneous

Outstanding Shares
43,328,000
Free Float
37,739,000
Market Cap
$2.67 billion
Optionable
Not Optionable
Beta
-0.12
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:GMTX) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners